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Background/Aims: Compared with Western countries, chronic lymphocytic leuke-
mia (CLL) rarely occurs in Asia and has different clinical characteristics. Thus, we 
aimed to evaluate the clinical characteristics, treatment outcomes, and prognostic 
significance of Korean patients with CLL. 
Methods: We retrospectively analyzed 90 patients with CLL who had received che-
motherapy at 6 centers in Korea between 2000 and 2012. 
Results: Compared with Western patients with CLL, Korean patients with CLL 
express lambda (42.0%) and atypical markers such as CD22 and FMC7 (76.7% and 
40.0%, respectively) more frequently. First-line chemotherapy regimens included 
chlorambucil (n = 43), fludarabine and cyclophosphamide (FC) (n = 20), fludarabine (n 
= 13), rituximab-FC (n = 4). The remaining patients were treated with other various 
regimens (n = 10). The 5-year overall survival (OS) and progression-free survival (PFS) 
rates were 79.3% and 28.1%, respectively. Multivariate analyses showed that hyper-
leukocytosis (≥ 100 × 103/μL), extranodal involvement, and the Binet C stage were sig-
nificant negative prognostic factors for OS (hazard ratio [HR] 4.75, p = 0.039; HR 21.6, 
p = 0.002; and HR 4.35, p = 0.034, respectively). Cytogenetic abnormalities including 
complex karyotypes (≥ 3), del(11q), and del(17) had a significantly adverse impact on 
both OS and PFS (p < 0.001 and p = 0.010, respectively). 
Conclusions: Initial hyperleukocytosis, extranodal involvement, complex karyotype, 
del(17) and del(11q) need to be considered in the risk stratification system for CLL.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is 
a mature B cell neoplasm, usually with 
coexpressed cluster of differentiation 
5 (CD5) and CD23 [1]. The diagnostic 
criteria of CLL requires the presence 
of at least 5 × 109/L monoclonal B lym-
phocytes with the CLL phenotype in 
peripheral blood [2]. To determine the 
disease extent and prognosis, Rai and 
Binet clinical staging systems have 
been used to predict the prognostic 
risks of CLL for > 3 decades [2-4]. With 
the advancement of genetic analysis 
techniques, genetic abnormalities were 
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found to have important clinical implications. Immu-
noglobulin heavy-chain variable (IGHV) gene somatic 
hypermutations are found in 50% to 60% of CLL cas-
es and are associated with more favorable outcomes 
[5,6]. About 80% of the patients have cytogenetic abnor-
malities detected by fluorescence in situ hybridization 
(FISH) [7]. Del(11q), del(17p), and del(6q) were associated 
with chemotherapy resistance and worse outcome [6]. 
Del(13q), however, has been known to predict a more fa-
vorable clinical course [7].
CLL is the most common type of leukemia in Western 
countries; however, CLL rarely occurs in Asian popu-
lations [8-10]. In Korea, the annual incidence of CLL is 
only 0.11 per 100,000 people, while that in the Western 
countries is 2.8 to 3.9 per 100,000 people, which is 25 
to 35 times higher than that in Korea [10,11]. Asian CLL 
has been reported to have different immunophenotypes 
and clinical characteristics [8,12]. Therefore, the clini-
cal outcomes and prognostic factors after chemothera-
py in Asian patients with CLL might be different from 
those of Western patients with CLL. However, only a 
few studies have been reported on CLL in Asia because 
of the limited patient population. Therefore, we aimed 
to investigate the clinical characteristics, treatment out-
comes, and prognostic significances of Korean patients 
with CLL.
METHODS
We retrospectively analyzed 90 newly diagnosed pa-
tients with CLL who received chemotherapy at one of 
six centers in Korea between 2000 and 2012. CLL di-
agnosis and response evaluation were based on the 
International Workshop on CLL criteria, updated in 
2008. Patients with small lymphocytic lymphoma were 
excluded in this study. Data on baseline clinicopatho-
logical features, treatment modalities, and outcomes 
were obtained from the medical records of each patient. 
Cytogenetics and FISH were performed using the bone 
marrow samples of 73 patients and 27 patients, respec-
tively, at the time of CLL diagnosis. Immunophenotyp-
ic data at CLL diagnosis were available in 66 patients. 
Surface antigen expression on leukemic blasts was de-
termined by 4-color flow cytometric analysis using ei-
ther the FACScan system and Cell Quest software or the 
FACSCanto system and FACS Diva software (all from 
Becton Dickinson, San Jose, CA, USA). A CD45 blast 
gating method was used to distinguish leukemic blasts 
from other cells. The following antibodies directed to 
membrane antigens were used for standard immuno-
phenotypic analyses of CLL cells: anti-CD3, anti-CD5, 
anti-CD7, anti-CD10, anti-CD19, anti-CD20, anti-CD22, 
anti-CD23, FMC7, surface membrane immunoglobulin 
(SmIg; kappa and lambda), HLA-DR (Becton Dickinson, 
Franklin Lakes, NJ, USA), and terminal deoxynucleotidyl 
transferase (TdT; Dako, Glostrup, Denmark). Positivity 
for each surface antigen was defined as expression on ≥ 
20% leukemic cells, except for TdT positivity, which was 
defined as expression on ≥ 10% leukemic cells. 
This study was approved by the Institutional Re-
view Boards (Konkuk University Medical Center, KUH 
1010527; and Ulsan University Hospital, 2015-04-008) of 
all the participating hospitals, Korea. Written informed 
consent by the patients was waived due to a retrospective 
nature of our study.
Statistical analysis 
Continuous variables were compared using Student’s t 
test, whereas categorical variables were analyzed using 
either the Pearson’s chi-square test, or Fisher’s exact 
test. Survival probabilities were estimated using the Ka-
plan-Meier, method and differences in survival distri-
butions were compared using the log-rank test. Overall 
survival (OS) was calculated from the date of CLL di-
agnosis to the date of death or last follow-up. Progres-
sion-free survival (PFS) was measured from the time of 
initial chemotherapy to the date of progression or death 
from any cause. Among patients attaining complete re-
mission (CR) after induction chemotherapy, relapse-free 
survival (RFS) was defined from the time of CR to the 
date of relapse, or death from any cause. After chemo-
therapy, the overall response rate was defined as CR 
plus the partial remission (PR) rates. Factors affecting 
CR achievement were determined by either Pearson’s 
chi-square test, or Fisher’s exact test. Factors affecting 
OS, PFS, and RFS were analyzed using the log-rank test 
in univariate analyses, and the Cox proportional hazard 
model in multivariate analyses. The following variables 
were included in the analysis of prognostic factors: age, 
white blood cell (WBC) and platelet counts, hemoglobin 
level, presence of constitutional symptoms, lymphade-
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nopathy or splenomegaly at CLL diagnosis, expression 
of each surface antigen on leukemic blasts, cytogenetics, 
Rai stage, Binet system, chemotherapeutic regimens, 
and responses following chemotherapy. All statistical 
analyses were performed using the SPSS version 21.0 
software (IBM Corp., Armonk, NY, USA). Variables with 
p < 0.1 in univariate analyses were included in the mul-
tivariate analyses. For all analyses, p values were 2 sided, 
and p < 0.05 was considered statistically significant. 
RESULTS
Patients
The baseline characteristics of the patients with CLL 
at diagnosis are listed in Table 1. The study population 
comprised 53 male and 37 female patients; the medi-
an age was 61.5 years (range, 25 to 93), and all included 
patients received systemic chemotherapy. The median 
time from diagnosis to treatment was 1.0 months (range, 
0 to 128.6). The clinical characteristics and chemothera-
peutic regimens at the time of chemotherapy are sum-
marized in Supplementary Table 1. Approximately 43.3% 
of all treated patients were treated in Rai stages III or IV. 
Patients having either symptoms related to CLL includ-
ing lymphadenopathy, splenomegaly, and constitution-
al symptoms or significantly high leukocyte counts were 
treated in Rai stage 0 (25.6%), I (14.7%), and II (15.6%). 
First-line chemotherapy comprised oral chlorambucil 
(n = 43, 47.8%), fludarabine and cyclophosphamide (FC) 
(n = 20, 22.2%); fludarabine alone (n = 13, 14.4%); fluda-
rabine, cyclophosphamide, and rituximab (FCR) (n = 4, 
4.4%); fludarabine and rituximab (FR) (n = 1 [1.1%]); and 
cyclophosphamide, vincristine, and prednisolone (CVP) 
(n = 4, 4.4%). The remaining patients (n = 5) received oth-
er various regimen including vincristine plus predniso-
lone (VP) or cyclophosphamide plus prednisolone. The 
second-line chemotherapies were administered in 52 
patients, of whom 16 received chlorambucil, and 12 re-
ceived fludarabine. In addition, FCR (n = 5), FC (n = 3), FR 
(n = 3), and other various regimens (n = 13) including CVP; 
VP plus cyclophosphamide, adriamycin, vincristine, and 
prednisolone (CHOP); rituximab plus CHOP (R-CHOP); 
and fludarabine, cyclophosphamide, and mitoxantrone 
(FCM) were administered as second-line chemotherapy. 
Third-line chemotherapy was performed in 26 patients. 
Table 1. Baseline characteristics at diagnosis
Characteristic Total (n = 90)
Sex, male/female (n = 90) 53 (58.9)/37 (41.1)
Age, yr (n = 950) 61.5 (25–93)
Hypertension (n = 89) 22 (24.4)
Diabetes mellitus (n = 89) 11 (12.2)
History of cancer (n = 90) 4 (4.4)
Comorbidity (n = 89)a 16 (17.8)
Constitutional symptom (n = 89) 14 (15.6)
Lymphadenopathy (n = 84) 45 (50.0)
Bulky lymph node (> 5 cm) (n = 90) 2 (2.2)
Hepatomegaly (n = 82) 4 (4.4)
Splenomegaly (n = 83) 28 (31.1)
Extranodal involvement (n = 90) 4 (4.4)
WBC count, × 103/μL (n = 90) 27.4 (3.83–447.4)
Hemoglobin, g/dL (n = 90) 12.6 (2.1–19.9)
Platelet, × 103/μL (n = 90) 175.5 (5–308)
Lymphocyte count, × 103/μL (n = 88) 22.8 (1.4–438.5)
Bone marrow cellularity, % (n = 68) 60 (10–100)
Bone marrow neoplastic cells, % (n = 63) 77.0 (9.0–96.1)
LDH (n = 73) 285 (112–1112)




Cytogenetics (n = 73)b




Trisomy 12 2 (2.2)
Complex karyotype (≥ 3) 3 (3.3)
Others 2 (2.2)
FISH 
IgH gene rearrangement (n = 20) 6
Del(13q) (n = 18) 7
Trisomy 12 (n = 21) 6
Del(11q) (n = 20) 2
Del(17p) (n = 25) 2
Values are presented as number (%) or median (range).
WBC, white blood cell; LDH, lactate dehydrogenase; FISH, 
f luorescence in situ hybridization; IgH, immunoglobulin 
heavy locus.
aComorbidity includes cerebrovascular disease, heart dis-
ease, liver disease, and lung disease other than hypertension, 
diabetes and prior cancers. 
bAt the time of diagnosis.
197
Choi Y, et al. Treatment outcomes of Korean CLL
www.kjim.orghttps://doi.org/10.3904/kjim.2019.210
Only two patients who achieved PR, and had stable dis-
ease after chemotherapy underwent allogeneic hemato-
poietic stem cell transplantation (allo-HCT). 
Immunophenotypic characteristics
Immunophenotypic findings of CLL patients are sum-
marized in Table 2. CD19 expression was observed in 
all tested patients with B cell CLL, except three with T 
cell-type CLL. Approximately 78.1% of all tested patients 
showed CD5 positivity, while 14 patients presented with 
atypical CLL (CD5 negative). Interestingly, CD22 and 
FMC7 positivity was frequently found in 76.7% (33/43) 
and 40.0% (12/30) of the patients, respectively. Expres-
sion of kappa and lambda SmIg were observed in 38.0% 
and 42.0% of the patients, respectively.
Chemotherapy responses
The clinical characteristics of patients at the time of 
chemotherapy are summarized in Supplementary Ta-
ble 1. Twelve patients (12.6%) presented with consti-
tutional symptoms such as fever, night sweats, or sig-
nificant weight loss (≥ 10% for 6 months). Among 45 
patients who received chemotherapy at Binet A, 40.0% 
had progressive higher WBC counts > 40.0 × 103/μL, 
52.5% had symptomatic lymphadenopathy or spleno-
megaly, and 11.4% had constitutional symptoms. After 
administering first-line chemotherapy, 18.9% of the 
patients achieved CR. The CR rate after the maximum 
third-line chemotherapy was 27.8%. Only two patients 
achieved a CR after third-line chemotherapy. The over-
all response rates were 70.0%, and 32.2% after first-, and 
second-line chemotherapy, respectively. Among the 25 
patients who achieved CR, 12 (48.0%) experienced re-
lapse. Two patients with refractory CLL who underwent 
allo-HCT survived after achieving CR status. The CR 
rates according to initial chemotherapeutic regimen are 
summarized in Table 3. The CR rates of the FCR, and 
FC regimens were 25%, and 35%, respectively (Table 3). 
There were, however, significant differences in the CR 
rate regarding cytogenetic abnormalities (p = 0.011) (Ta-
Table 2. Immunophenotypic characteristics 
Immunophenotype (patient no. analyzed 
 for the immunophenotype)
No. of positive 
patient (%)
CD3 (+) (n = 40) 3 (7.5)
CD5 (+) (n = 64) 50 (78.1)
CD7 (+) (n = 55) 4 (7.3)
CD19 (+) (n = 66) 63 (95.5)
CD20 (+) (n = 57) 54 (94.7)
CD22 (+) (n = 43) 33 (76.7)
CD23 (+) (n = 41) 37 (90.2)
CD45 (+) (n = 22) 22 (100)
CD56 (+) (n = 16) 0 
FMC7 (+) (n = 30) 12 (40.0)
HLA-DR (+) (n = 24) 24 (100)
TdT (+) (n = 29) 3 (10.3)
SmIg (n = 50)
Kappa (+) 19 (38.0)
Lambda (+) 21 (42.0)
Negative 10 (20.0)
TdT, terminal deoxynucleotidyl transferase; SmIg, surface 
membrane immunoglobulin.
Table 3. Treatment outcomes after chemotherapy
Variable CR rate
Response  
rate (CR + PR)
1st line chemotherapy 
regimen (n = 90)
Chlorambucil (n = 43) 7 (16.3) 29 (67.5)
Fludarabine (n = 13) 1 (7.7) 7 (63.6)
FCR (n = 4) 1 (25) 3 (75.0)
FC (n = 20) 1 (35.0) 18 (90)
CVP (n = 4) 0 3 (75.0)
RF (n = 1) 0 1 (100)
Others (hydroxyurea, VP, 
 Cy + PD) (n = 5)
0 2 (40.0)
Cytogenetics (n = 73)a p = 0.011
IgH rearrangement (n = 6) 4 (66.7)
Normal karyotype/ 
 others (n = 62)
11 (17.7)
Del(11q)/del(17)/CK (n = 5) 0 
Values are presented as number (%).
CR, complete remission; PR, partial remission; FCR, fluda-
rabine, cyclophosphamide, and rituximab; FC, fludarabine 
and cyclophosphamide; CVP, cyclophosphadmie, vincris-
tine and prednisolone; RF, rituximab and fludarabine; VP, 
vincristine and prednisolone; Cy + PD, cyclophosphadmie 
and prednisolone; IgH, immunoglobulin heavy locus; CK, 
complex karyotype.
aAt the initiation of first-line chemotherapy. 
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ble 3). Patients with immunoglobulin heavy locus (IgH) 
rearrangement showed a significantly higher CR rate 
than those with no IgH rearrangement (66.7% vs. 17.2%, 
respectively; p = 0.011). However, patients with del(11q), 
del(17), or complex karyotype (≥ 3 chromosomal abnor-
malities) did not achieve CR.
Univariate analysis for survival outcomes
The median follow-up duration for surviving patients 
was 80.5 months (range, 2.0 to 167.8). The 5-year survival 
rate for all included patients was 79.3%, and the median 
OS was not reached (Fig. 1A). During the follow-up peri-
od, 23 patients with persistent disease died, either from 
infection (n = 12), or disease progression (n = 11). After 
the initial chemotherapy regimen, the median PFS was 
31.0 months (95% confidence interval [CI], 23.1 to 39.1) 
and the 5-year PFS rate was 28.1% (Fig. 1B). The medi-
an RFS of the 25 patients who achieved CR after chemo-
therapy was 50.3 months (95% CI, 8.6 to 91.9), while 12 
patients experienced relapse. The 5-year RFS rate for the 
patients who achieved CR was 47.3%. Univariate analyses 
for OS and PFS according to the clinical parameters are 
summarized in Table 4. The traditional staging criteria 
according to Rai system and Binet system had signifi-
cant effects on the OS (p = 0.001, and p = 0.006, respec-
tively). Lymphadenopathy, splenomegaly, and extranod-
al involvement were significantly associated with lower 
OS rates (p = 0.029, p = 0.003, and p = 0.008, respectively). 
Initial hyperleukocytosis (WBC ≥ 100 × 103/μL), anemia 
(hemoglobin < 10 g/dL), and thrombocytopenia (platelet 
count < 80 × 103/μL) were significantly associated with 
worse OS (p < 0.001, p = 0.004, and p = 0.032, respectively). 
In contrast to the risk classification of the Rai and Binet 
systems, in which platelet count less than 100 × 103/μL 
was associated with worst prognosis, our data showed 
that patients with a platelet count between 80 × 103 and 
110 × 103/μL had survival rates comparable to those with 
higher platelet counts (> 110 × 103/μL) (5-year OS rate: 
92.9% vs. 82.0%, respectively), whereas those with a low-
er platelet count (< 80 × 103/μL) had a significantly low-
er OS rate (46.7%, p = 0.032). In addition, the univariate 
analyses revealed that higher proportions of neoplastic 
cells in the bone marrow (≥ 80%), and higher lactate 
dehydrogenase (LDH) (≥ 500 IU/L) levels were signifi-
cantly associated with worse OS rates (p = 0.021, and p = 
0.003, respectively). In particular, higher LDH levels (> 
500 IU/L) were also an adverse factor for predicting PFS 
(p = 0.016). Lymphadenopathy tended to be associated 
with worse PFS (p = 0.067). Cytogenetic abnormalities 
had a significant impact on OS and PFS (p = 0.002 and 
p = 0.006, respectively). IgH gene rearrangement was a 
significant favorable factor for OS (5-year OS and PFS: 
100% and 50%, respectively). Compared with normal 
karyotypes and other karyotypes, del(11q), del(17), and 
complex karyotypes (≥ 3 chromosomal abnormalities) 
were significant negative prognosticators (5-year OS and 
PFS rates: 82.9% vs. 26.7%, p = 0.002; and 29.7% vs. 0%, p 
= 0.006, respectively). 
With regard to immunophenotypic markers, expres-
sion of lambda SmIg showed a significantly worse PFS 
compared to expression of kappa SmIg, or the absence 
of both (5-year PFS rate: 6.3% vs. 40.4%, and 21.1%, re-
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Table 4. Univariate analysis for survivals
Variable 5-year OS, % p value 5-year PFS, % p value
Sex, male/female (n = 90) 76.4/84.3 0.544 24.3/32.8 0.701
Age, < 65/≥ 65 yr (n = 90) 85.0/68.8 0.224 30.6/21.0 0.235










Constitutional symptom (+/–) (n = 89), % 76.4/84.3 0.266 25.4/26.9 0.869
Lymphadenopathya (+/–) (n = 84) 68.5/86.9 0.029 24.2/36.3 0.127
Splenomegaly a (+/–) (n = 83), % 63.4/84.0 0.003 33.2/25.7 0.340
Extranodal involmenta (+/–) (n = 90), % 37.5/81.0 0.008 50.0/27.9 0.639
WBC count a, < 100/≥ 100 × 103/μL (n = 90) 83.9/28.6 < 0.001 29.3/14.3 0.049
Hemoglobin b, < 10/≥ 10 g/dL (n = 89) 55.9/85.7 0.004 11.8/30.6 0.056
Platelet b, < 80/80 to < 110/≥ 110 × 103/μL (n = 90) 46.7/92.3/81.7 0.032 13.3/0/33.3 0.174
Bone marrow neoplastic cells, < 80%/≥ 80% (n = 63) 88.0/73.1 0.021 28.7/41.4 0.296
LDH, < 500/≥ 500 IU/L (n = 70) 84.3/34.3 0.003 28.8/0 0.016
Cytogenetics (n = 75)a 0.002 0.006
IgH mutation 100 50.0
Normal karyotype/other chromosomes 82.3 29.7
Del(11q) or del(17) or CK 26.7 0
Immunophenotyping, %
SmIg (n = 50) 0.623 0.572
Kappa (+) 83.1 35.6
Lambda (+) 76.0 13.6
Negative 87.5 21.1




CD20 (n = 30) 0.138 0.058
Bright 90.0 53.5
Intermediate/dim/negative 76.9 12.7
Initial chemotherapy regimen (n = 90) 0.255 0.007
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spectively, p = 0.040). The bright expression of CD5 was 
significantly associated with a worse PFS, compared to 
intermediate or dim/negative expression of CD5 (0% 
vs. 21.6, and 29.3%, respectively, p = 0.018). On the con-
trary, patients with bright expression of CD20 tended 
to show higher PFS rates than those with intermediate 
or dim expression of CD20 (53.5% vs. 12.7%, p = 0.058). 
Apart from light chain, CD5, and CD20 expression, there 
were no significant differences in the survival outcomes 
among patients in terms of other immunophenotypic 
markers. 
The initial chemotherapy regimens including FCR or 
RF, FC, chlorambucil, fludarabine, and other various reg-
imens, significantly affected the 5-year PFS (53.3%, 46.6%, 
23.0%, 15.4%, and 12.5%, respectively, p = 0.007) and RFS 
rates (100%, 87.5%, 18.2%, 0%, and 0%, respectively, p = 
0.004), although there was no significant difference in 
OS (p = 0.255). The response after initial chemotherapy 
was a significant predictor of OS (p < 0.001) and PFS (p < 
0.001) (Table 4). All patients who achieved a CR even after 
second-, or third-line chemotherapy, or allogeneic stem 
cell transplantation survived more than 5 years.
Multivariate analysis
Multivariate analysis showed that initial hyperleukocy-
tosis (WBC count ≥ 100 × 103/μL) (HR, 4.748; p = 0.039) 
and extranodal involvement (HR, 21.639; p = 0.002), Binet 
stage C (HR, 4.354; p = 0.034), and chromosomal abnor-
malities including del(11q), del(17), or complex karyotype 
(≥ 3 chromosomal abnormalities) (HR, 17.022; p < 0.001) 
were powerful adverse prognostic factors for OS and 
PFS (HR 17.022; p < 0.001; and HR 9.620; p = 0.010; re-
spectively) (Table 5). Moreover, the light chain types of 
SmIg had a significant impact on PFS.
DISCUSSION
Among hematologic malignancies, CLL is a disease that 
demonstrates the greatest genetic differences between 
Western and Asian people [9]. CLL rarely occurs in Ko-
rean people, and only 56 patients are newly diagnosed 
with CLL annually [8]. The number of Korean patients 
with CLL has been slowly increasing [13]. The crude in-
cidence rate of CLL or small lymphocytic lymphoma 
has increased from 0.19, to 0.31 between 1999 and 2012 
according to the national cancer statistics [13]. Korean 
patients with CLL in our study were relatively young, 
with a median age at diagnosis of 61 years. In contrast, 
the median age at diagnosis in the United States is 70 
years [9,14]. In general, younger age may favorably affect 
the treatment outcomes of hematologic malignances. 
However, CLL occurring in Asian people showed a more 
aggressive progression than that occurring in Caucasian 
people [14]. Gunawardana et al. [14] reported that Asian 
patients required treatment almost twice as often as 
Caucasian patients (HR, 1.94) and had a shorter time to 
first treatment (p = 0.0063). A previous study from India 
suggested that a higher proportion of patients with CLL 
presented with an advanced clinical stage [15].
Variable 5-year OS, % p value 5-year PFS, % p value
Others 88.9 12.5





OS, overall survival; PFS, progression-free survival; WBC, white blood cell; LDH, lactate dehydrogenase; IgH, immunoglob-
ulin heavy locus; CK, complex karyotype; CD, cluster of differentiation; FCR, fludarabine, cyclophosphamide, and rituximab; 
RF, rituximab and fludarabine; FC, fludarabine and cyclophosphamide; CR, complete remission; PR, partial remission; SD, 
stable disease; PD, progressive disease.
aAt diagnosis. 
bAt the initiation of first-line chemotherapy. 
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201
Choi Y, et al. Treatment outcomes of Korean CLL
www.kjim.orghttps://doi.org/10.3904/kjim.2019.210
In the present study, Korean patients with CLL ex-
pressed a unique immunophenotypic pattern on the 
CLL cells. Compared with Western data, expression of 
atypical immunophenotypic markers such as CD22 and 
FMC7 were frequently observed among Korean CLL pa-
tients. Similarly, these findings were previously report-
ed in a small retrospective study conducted by Jang et al. 
[12]. In addition, expression of lambda SmIg was more 
frequent among Asian patients with CLL than among 
Western patients. Even though there were no signifi-
cant differences in univariate and multivariate analysis, 
lambda SmIg expression tended to be associated with 
a worse PFS compared with kappa SmIg expression. 
Therefore, compared to CLL observed among West-
ern patients, a relatively greater proportion of patients 
with lambda SmIg expression in Korean patients with 
CLL might influence the treatment outcome, which was 
worse than that of Western patients with CLL. In terms 
of the clinical implication of immunophenotypic mark-
ers, we found that the intensity of the CD5 and CD20 ex-
pression was more important than the positivity there-
of. Bright CD5 expressions was a significant predictor 
for worse PFS, compared to both intermediate-, and 
dim/negative expression. 
Among the first-line chemotherapeutic regimens, the 
FCR and FC regimens achieved a CR rate of 25%, and 
response rate of 75%. The FCR regimen has been recom-
mended as first-line chemotherapy in patients younger 
than 65 years without significant comorbidities accord-
ing to the 2018 National Comprehensive Cancer Net-
work guidelines [16]. The CR and response rates of Kore-
an patients with CLL treated with FCR seems to be lower 
than that reported in the CLL10 study [16]. Relatively 
smaller numbers of patients received rituximab-con-
taining chemotherapy as first-, or second-line chemo-
therapy in our data. Nowadays, several novel agents 
including the Bruton’s tyrosine kinase inhibitor (ibru-
tinib), anti-CD20 monoclonal antibody (obinutuzumab), 
bendamustine, and ofatumumab have been introduced 
as first-line therapy for CLL [8,17-19]. Unfortunately, 
the national medical insurance reimbursement system 
in Korea does not cover the expenses for the procure-
ment of those novel agents as first-line chemotherapy 
for CLL. Therefore, our data have some limitations, as 
we were unable to include the therapeutic experiences 
of patients who were treated using newer agents. 
OS of Korean patients with CLL who received chemo-
therapy was not reached, and the 5-year PFS rate was only 
28.1%. Although the Rai, and Binet staging systems were 
introduced more than 37 years ago, these two prognostic 
systems have been widely used to stratify the prognosis 
of patients with CLL [3,4]. With regard to the therapeutic 
outcome prediction in CLL, genetic abnormalities have 
important clinical implications. There might be ethnic 
differences in the clinical implication of genetic aberra-
tions, including IgH mutations. In our study, IgH gene 
rearrangement was associated with a higher CR rate. In 
the CLL10 study, however, IgH mutations had no influ-
Table 5. Multivariate analysis
Variable
Overall survival Progression-free survival
HR (95% CI) p value HR (95% CI) p value
WBC count, ≥ 100, × 103/μLa 4.748 (1.084–20.792) 0.039 - -
Extranodal involvementa 21.639 (2.972–157.553) 0.002 -
Binet systema
A Reference -
B 0.455 (0.040–5.108) 0.523 -
C 4.354 (1.117–16.975) 0.034 -
Cytogeneticsa 
Normal karyotype/other chromosomes Reference Reference
Del(11q) or del(17) or CK 17.022 (3.674–78.864) < 0.001 9.620 (1.732–53.444) 0.010
IgH mutation - 0.988 0.503 (0.114–2.215) 0.364
HR, hazard ratio; CI, confidence interval; WBC, white blood cell; CK, complex karyotype (≥ 3); IgH, immunoglobulin heavy locus.
aAt the time of diagnosis.
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ence on either CR rate, or overall response rate in both 
treatment arms (FCR vs. bendamustine and rituximab) 
[16]. Del(11q), del(17p), and del(6q) have been reported 
to be associated with a worse outcome [6,7]. Previous 
large-scale studies reported that patients with del(17p) 
and TP53 mutations had poorer chemotherapy respons-
es and survival rates [20-22]. We also demonstrated that 
patients with a complex karyotype (≥ 3 cytogenetic ab-
normalities) as well as del(11q) and del(17p) were import-
ant adverse factors in terms of CR achievement, OS, and 
PFS in patients with CLL. None of the patients with a 
complex karyotype (≥ 3) as well as del(11q) and del(17p) 
attained a CR after chemotherapy. In CLL, the prognos-
tic significance of a complex karyotype had also been 
reported in other recent studies [23-25]. 
For the prediction of CLL prognosis, Wierda et al. 
[26] suggested that age, absolute lymphocyte count, beta 
2-microglobulin, sex, and nodal involvement were sig-
nificant prognostic factors in addition to Rai staging. 
Similarly, we also demonstrated that hyperleukocytosis 
(≥ 100 × 103/μL) was an independently significant poor 
prognostic factor for Korean patients with CLL. Where-
as traditional prognostic stratification systems such as 
the Rai and Binet systems cannot reflect tumor bur-
dens, hyperleukocytosis (≥ 100 × 103/μL) as well as the 
proportion of neoplastic cells in the bone marrow (≥ 
80%), and higher LDH (≥ 500 IU/L) levels, which might 
reflect tumor burden, were also important factors affect-
ing treatment outcomes in Korean patients with CLL, as 
shown in our univariate analysis of the survival rates. In 
addition, extranodal involvement was a poor prognostic 
factor, although extranodal involvement was only found 
in 4.2% of the patients in our study. The extranodal sites 
involved were pleura, cerebrospinal fluid (CSF), brain, 
parotid gland, and nasopharynx.
We also found that mild thrombocytopenia (platelet 
count between 80 × 103/μL and 110 × 103/μL) did not have 
a poor prognostic significance in our data. The surviv-
al of patients with platelet counts between 80 × 103/μL 
and 110 × 103/μL was not different from that of patients 
with a platelet count > 110 × 103/μL. Traditionally, ac-
cording to the Rai and Binet staging systems, patients 
with thrombocytopenia (platelet count: < 100 × 103/μL, 
irrespective of organomegaly) were categorized into the 
worst prognostic group, stage IV and stage C, respective-
ly [3]. In contrast to the results of previous studies using 
clinical staging systems such as Rai and Binet systems, 
the German CLL Study Group (GCLLSG) data, or the 
CLL international prognostic index (CLL-IPI) [3,4,6,22], 
our data showed that a platelet count < 80 × 103/μL had 
poor prognostic significance. Therefore, we suggest that 
thrombocytopenia needs to be more stratified in Korean 
patients with CLL. If patients have a platelet count > 80 
× 103/μL without any other therapeutic indications for 
CLL such as progressive organomegaly, severe anemia, 
and constitutional symptoms, a more conservative ap-
proach might be acceptable, and chemotherapy might 
be deferred for these patients. 
Our data have several limitations. This study is ret-
rospective in nature, included a small number of pa-
tients, and had limited FISH data. Our study population 
had limited exposure to newer therapeutic agents such 
as rituximab. However, our results showed the unique 
clinical characteristics and implications of CLL among 
Korean patients, including its clinical factors and im-
munophenotypic features and more stratified addition-
al prognostic factors.
Although a diagnosis of CLL requires the presence of 
≥ 5 × 109/L B lymphocytes in the peripheral blood, sus-
tained for at least 3 months [27], some patients with CLL 
in the present study have less than 5 × 109/L B lympho-
cytes. According to the 2008 International Workshop on 
Chronic Lymphocytic Leukemia, the presence of a cyto-
penia caused by a typical marrow infiltrate establishes 
the diagnosis of CLL regardless of the number of pe-
ripheral blood B lymphocytes, or the presence of lymph 
node involvement [27].
To the best of our knowledge, this is the first multi-
center retrospective study to analyze the treatment out-
comes and prognostic factors of Korean patients with 
CLL who received first-line chemotherapy. Considering 
the rarity of CLL in Asia, our sample size is not really 
small.
In conclusion, Korean patients with CLL have differ-
ent characteristics in terms of the frequency of lambda 
SmIg expression and atypical CD22 and FMC7 marker 
positivity. Hyperleukocytosis, extranodal involvement, 
Binet stage C, a complex karyotype, del(17) and del(11q) 
were independent significant negative predictors. We 
suggest that our results might be incorporated in a bet-
ter risk stratification system of CLL in the future.
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Supplementary Table 1. Clinical characteristics at the time 
of chemotherapy and treatment outcomes













Constitutional symptom (n = 88) 12 (13.3)






Death in cytopenia 1 (1.1)
Values are presented as number (%).
CR, complete remission; PR, partial remission; SD, stable 
disease; PD, progressive disease.
